🚨 #ESMO26 | DeLLphi-305 (Phase 3)
Tarlatamab + durva vs durva as 1L maintenance in ES-SCLC after chemo-IO (N=563)
✅ mOS 21.1 vs 12.7 mo (HR 0.42)
✅ mPFS 7.4 vs 1.9 mo (HR 0.34)
✅ ORR 26.4% vs 4.1%
⚠️ CRS 49.6% (G≥3 0.4%)
A new 1L maintenance standard 🫁
#SCLC #LungCancer
@myESMO @OncoAlert
152 浏览 · 1 赞 · 1 转发 · 1 回复
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.org- Ahmed Alanazi | أحمد العنزي@alanazi002
💡Takeaway: a 58% reduction in risk of death moves tarlatamab into frontline maintenance. Practical questions now: CRS monitoring logistics (inpatient vs outpatient for the first doses), and the 2L sequence after progression on tarlatamab.
来源：Ahmed Alanazi | أحمد العنزي · x.com